- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer (PC)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 604KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 112KB)
Talazoparib – July 2024
Talazoparib; Capsule 0.1 mg, Capsule 0.25 mg, Capsule 0.35 mg, Capsule 0.5 mg; Talzenna®
Last updated
30 May 2025